Table 4.

ADCs in late clinical development with a biological macromolecule drug payload and their key features.

ADC Name	Target	Payload	Linker	Phase
cintredekin besudotox 1	IL-13R	Pseudomonas exotoxin A	fusion	3
E7777 2	IL-2R	Diptheria Toxin A,B	fusion	3
oportuzumab monatox 3	EpCAM	Pseudomonas exotoxin A	fusion	3
T-Guard 4	CD7 and CD3	Ricin A	undisclosed	3
naptumomab estafenatox 5	5T4	Staphylococcal Enterotoxin E	fusion	2/3
Proxinium 6	EpCAM	Pseudomonas exotoxin A	fusion	2/3
EP-100 7	LHRH	CLIP-71	fusion	2
L-DOS47 8	CEACAM6	Urease	SIAB	2
LMB-2 9	CD25	Pseudomonas exotoxin	fusion	2
MDNA55 10	IL-4R	Pseudomonas exotoxin A	fusion	2
MT-3724 11	CD20	Shiga-like toxin A	fusion	2
Resimmune 12	CD3	Diphtheria toxin	fusion	2
RO6927005 13	MSLN	Pseudomonas exotoxin A	fusion	2

¹ fusion protein of IL-13 and a modified toxin. ² fusion protein of IL-2 and modified toxins. ³ fusion protein of a single chain fragment of a mAb and a toxin. ⁴ combination of a DD7 targeting ADC and a CD3 targeting ADC. ⁵ fusion protein of the Fab portion of a 5T4 mAb and a toxin. ⁶ fusion protein of a single chain fragment of a mAb and a toxin. ⁷ a LHRH natural ligand (10 amino acids) joined to an 18 amino acid cationic α-helical lytic peptide. ⁸ conjugate of a single domain camelid antibody and Jack bean urease enzyme through a N-succinimidyl[4-iodoacetyl] aminobenzoate linker. ⁹ fusion of the variable heavy domain of anti-CD25 and a modified toxin. ¹⁰ fusion protein of IL-4 and a modified toxin. ¹¹ fusion protein of the variable fragment of a mAb and a toxin. ¹² fusion of a modified toxin with two single chain antibody fragments. ¹³ fusion protein of a Fab mAb fragment and a modified toxin.